HCC incidence and recurrence after DAAs: new insights

References

[1] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[2] Veldt BJ,Wedemeyer H,Hofmann WP.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis..Ann Intern Med2007;147:677-84

[3] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virüs infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies..Ann Intern Med2013;158:329-37

[4] El-Seraq HB.,Richardson P..Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection..Hepatology2016;64:130-7 PMCID:PMC4917456

[5] Nault JC.Hepatocellular carcinoma and direct acting antiviral treatments:Controversy after the revolution..J Hepatol2016;65:663-5

[6] Nishiguchi S,Nakatani S,Takeda T.Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis..Lancet1995;346:1051-5

[7] Reig M,Perello C,Ribeiro A.Unexpected high rate of early tumour recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[8] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma..Ann Intern Med2013;158:329-37

[9] Ravi S,Jones D,Simpson H.Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis..Gastroenterology2017;152:911-3

[10] Cardoso H,Rodrigues S,Albuquerque A.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis..J Hepatol2016;65:1057-71

[11] Yang JD,Pungpapong S,Roberts LR.Direct acting antiviral therapy and tumour recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma..J Hepatol2016;65:856-68

[12] Beste LA,Berry K,Allison S.Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma..J Hepatol2017;67:32-9

[13] Yoshida H,Moriyama M,Ide T.Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy..Ann Intern Med1999;131:174-81

[14] Moon C,Kim DY,Park JY.Lower incidence of hepatocelluler carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin..Dig Dis Sci2015;60:573-81

[15] Innes H,Hayes PC,Dillon JF.The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen..J Hepatol2018;68:646-54

[16] Telep LE,Osinusi A,Reddy KR.No ıncreased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data..J Hepatol2017;66:S333-542

[17] Li DK,Fierer DS,Shaikh OS.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with Direct-acting antivirals: an ERCHIVES study..Hepatology2018;67:2244-53

[18] Petta S,Barbara M,Bucci L.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon..Aliment Pharmacol Ther2017;45:160-8

[19] Cabibbo G,Calvaruso V,Cannavo MR.Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study..Aliment Pharmacol Ther2017;46:688-95

[20] Virlogeux V,Hartig-Lavie K,Maynard M.Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C..Liver International2017;37:1122-7

[21] Mettke F,Deterding K,Smith A.Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis..Aliment Pharmacol and Ther2018;47:516-25

[22] Calvaruso V,Cacciola I,Madonia S.Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents..Gastroenterology2018;155:411-21

[23] Marco VD,Ferraro D,Cabibbo G.Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension..Gastroenterology2016;151:130-9

[24] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents..Gastroenterology2017;153:996-1005

[25] Romano A,Piovesan S,Anastassopoulos G.Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study..J Hepatol2018;69:345-52

[26] Breitenstein S,Petrowsky H,Müllhaupt B.Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis..Br J Surg2009;96:975-81

[27] Minami T,Nakagomi R,Sato M.The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma..J Hepatol2016;65:1261-73

[28] Idilman R,Aladag M,Cavus B.Low recurrence rate of Hepatocellular carcinoma following Ledipasvir and Sofosbuvir treatment in a real-world chronic hepatitis C patients cohort..J Viral Hepat2019;